The Kymouse™ platform, with the entire repertoire of human antibody diversity is able to mimic a normal humoral immune response and is an excellent technology to evaluate vaccine antigens. When immunized with candidate antigens or infected with pathogenic organisms, the Kymouse™ mounts an immune response and matures antibodies from their human building blocks.
The Kymouse™ has more than 5.4 million base-pairs of the human immunoglobulin locus in their genome. With a human antibody repertoire, Kymouse™ provides an experimentally accessible surrogate for assessing normal human immune responses, enabling the identification of therapeutic antibodies and determining vaccine efficacy in pre-clinical models of infection.
Kymab is able to immunise Kymouse™ with a defined immunogen and then identify and isolate monoclonal antibodies that reliably bind the antigen with desired properties. An appropriate immunogen is therefore a means of eliciting a protective immune response to a given pathogen and a tool for discovering therapeutic antibodies to treat a given disease. Consequently, it is possible to build processes for vaccine efficacy development and therapeutic antibody discovery, simultaneously.
The IntelliSelect™ system at Kymab, captures relevant antibody sequences from single B-cells, provides understanding of their evolutionary relationships, and can convert them into expression vectors to generate recombinant antibodies for high-throughput assays. Once a lead antibody has been identified, Kymab can deeply mine the repertoire to discover related antibodies with unique and potent therapeutic properties.
Sok D, Briney B, Jardine JJ, Kulp DW et al. (2016) Priming HIV-1 broadly neutralizing antibody precursors in human Ig loci transgenic mice. Science 353(6307):1557-1560 30 September, 2016.